ArticleAmerican journal of preventive cardiology2026
Incremental prognostic value of coronary artery calcium progression within a large community-benefit calcium score registry.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04075162 (Community Benefit of No-charge Calcium Score Screening Program), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Community Benefit of No-charge Calcium Score Screening Program
Who cites it
1 citing paper in PubMed.
- The future of CV prevention science depends on how we communicate: why simultaneous publication matters.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery calcium (CAC) scoring is a robust cardiovascular risk marker, yet the prognostic value of serial assessment and the relative importance of incident calcium versus progression from elevated baseline CAC remains incompletely defined. Methods: We analyzed 4166 CLARIFY registry participants (NCT04075162) who underwent ≥2 CAC scans ≥11 months apart (mean interval 4.5 years). Defining CAC progression (ΔCAC>10 Agatston units, AU) identified 1982 progressors and 2184 non-progressors. Annualized absolute, square-root, and log-transformed progression were evaluated for association with major adverse cardiovascular events (MACE: myocardial infarction, stroke, mortality, revascularization, and heart failure). Incremental prognostic value was assessed by adding annualized progression to the base MESA-CAC model incorporating baseline CAC, demographics, and traditional risk factors. Results: Over a median 5.9 year follow-up, progressors had higher MACE incidence, though risk gradients differed by baseline CAC. Incident CAC from a baseline zero score was not associated with increased MACE (all Conclusions: Serial CAC imaging may provide incremental prognostic value in individuals with pre-existing atherosclerosis. While incident CAC after a baseline zero score may confer limited short-term risk, it may present a window for preventive intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.